ACE2-(G4S)6-FC

ACE2-(G4S)6-FC is a recombinant fusion protein designed as a bivalent, flexibly linked decoy receptor for SARS-CoV-2 and other viruses that use angiotensin-converting enzyme 2 (ACE2) as an entry receptor. The molecule consists of two extracellular domains of human ACE2 connected by six repeats of the flexible glycine-serine linker (G4S), fused to the Fc region of human IgG. This design enhances binding affinity and neutralization potency compared to non-flexibly linked or monomeric forms. The drug acts by binding to the viral spike protein with high affinity, thereby preventing viral entry into host cells and neutralizing all tested variants of SARS-CoV-2, including Omicron. It is formulated for inhaled delivery, enabling direct administration to the respiratory tract where infection occurs. Preclinical studies have demonstrated potent antiviral activity in animal models with significant reductions in viral load following intranasal dosing[1][3][6].

Other names

flexibly linked ACE2-Fc decoymuco-trapping ACE2-(G4S)6-FC decoy